glp-1 drugs for insulin resistance Comparing Ozempic, Wegovy and Other GLP-1 drugs effective for type

Limitations The major limitations of the studies that are included in this systematic review are the enrollment of healthy subjects and insufficient data in conditions that might affect pharmacokinetics (e.g., kidney dysfunction)

Online Journal | Justin Plank | January 2025 Background Every year, the United States spends an estimated $173 billion treating obesity-related diseases like diabetes and heart disease, more than the annual budgets of 42 U.S

This state-of-the-art narrative review synthesizes current evidence from clinical trials, pharmacovigilance databases, and real-world cohorts to provide a comprehensive evaluation of the safety and tolerability of GLP-1RAs and tirzepatide

Patient safety cannot be compromised in the rush for growth

With drugs like Ozempic and Wegovy growing in popularity among diabetic patients, CRNAs must be aware of all potential GLP-1 and anesthesia conflicts.

Back in 1990, an endocrinologist named John Eng was